Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is DaVita HealthCare Partners Inc (DVA) Worth a Buy?

Page 1 of 2

In order to be successful in investing, just pick a great company and stick with it through ups and downs. That is what Charlie Munger often advises investors to do. Indeed, Warren Buffett has become a better investor when his investment philosophy shifted towards great quality businesses. Recently, Berkshire Hathaway Inc. (NYSE:BRK.A) has been adding shares of DaVita HealthCare Partners Inc (NYSE:DVA) to its portfolio, even as its share price reached its all time high of $123.35 per share. That might be Ted Weschler’s decision, as he has been a DaVita shareholder for more than 12 years.

Let’s take a closer look to see whether or not DaVita HealthCare Partners Inc (NYSE:DVA) should be a long-term stock in value investors’ portfolios.

DaVita HealthCare Partners Inc (NYSE:DVA)Business snapshot

DaVita HealthCare Partners Inc (NYSE:DVA) is considered one of the leading providers of kidney dialysis services in the U.S. In 2012, the company provided dialysis services via the network of more than 1,950 dialysis centers for about 153,000 patients. With the recent acquisition of HCP, Inc. (NYSE:HCP) in November 2012, DaVita HealthCare Partners Inc (NYSE:DVA) entered the business of patient and physician-focused integrated healthcare delivery and management. In 2012, HCP had around 724,000 members in different areas, including Southern California, southern Nevada, and Florida. The majority of its revenue, $7.1 billion, or 86% of the total revenue, was generated from the U.S. dialysis segment while the HCP segment contributed $477 million in 2012 revenue, accounting for 5.8% of the total revenue. Assuming that HCP was acquired in the beginning of 2012, on a pro forma basis, U.S. dialysis would have accounted for 68% of the total revenue, while HCP would have accounted for 26% of the total revenue.

A huge growth and reasonable debt level

At first glance, DaVita seems to be over-leveraged. As of December 2012, DaVita HealthCare Partners Inc (NYSE:DVA) had nearly $3.93 billion in total stockholders’ equity, $533.75 million in cash and more than $8.55 billion in both long and short-term debt. In 2012, the amortizable intangible amount increased significantly, from $159.5 million in 2011 to nearly $2.13 billion in 2012, mainly due to nearly $1.49 billion in customer relationships. However, the debt maturities were spread out over many years.

Source: DaVita’s 10-K filing

With a yearly EBITDA of $1.74 billion, I personally think that DaVita HealthCare Partners Inc (NYSE:DVA) could be quite comfortable to cover interest expenses and debt principals. Moreover, DaVita has demonstrated an impressive operating performance record for the past 10 years. Its revenue has increased four times, from $2 billion in 2003 to nearly $8.19 billion in 2012, whereas its earnings rose significantly from $176 million, or $1.66 per share, to $536 million, or $5.47 per share, in the same period. Interestingly, its share count has been shrinking by 14%, from 114 million shares in 2003 to around 98 million shares in 2012.

Second player in dialysis industry

DaVita HealthCare Partners Inc (NYSE:DVA) ranked second in the industry, behind its main competitor Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS), which has more than 3,160 global dialysis clinics to treat nearly 260,000 patients worldwide. The two companies combined accounted for around two-thirds of outpatient dialysis patients in the U.S. Interestingly, both companies have been strategic partners for several years. DaVita has purchased some dialysis equipment from Fresenius since 2010. In January, those two companies signed an agreement for providing certain pharmacy services to Fresenius’s Medicare patients in the U.S.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!